ERBB2 and breast carcinoma: The recurrence rate and mortality of TNBC are higher than those of other breast cancer subtypes, and patients do not benefit from endocrine therapy or HER2-targeted therapy, particularly within the first 3 to 5 years following diagnosis [23].